On Jun 29, 2018 Xenon Pharmaceuticals Inchares (NASDAQ:XENE) Shorts Strengthened By 5.71%

June 29, 2018 - By Rebecca Betts

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Corporate Logo

Xenon Pharmaceuticals Inchares (NASDAQ:XENE) reported an increase of 5.71% in shorted shares. In June was issued XENE’s total 148,000 shorted shares by FINRA. The 140,000 previous shares are up with 5.71%. 1 days will cost XENE with 155,300 average volume to restore its previous position. 1.28% is Xenon Pharmaceuticals Inchares float short.

XENE hit $9.7 during the last trading session after $1.05 change.Xenon Pharmaceuticals Inc. is uptrending after having risen 39.24% since June 29, 2017. XENE has 776,200 volume or 326.27% up from normal. XENE outperformed by 26.67% the S&P 500.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada.The firm is valued at $137.47 million. The firm uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.Last it reported negative earnings. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency.

Another two news for Xenon Pharmaceuticals Inc. (NASDAQ:XENE) were recently announced by: Benzinga.com on June 13, 2018 with title “42 Biggest Movers From Yesterday”. The other Benzinga.com‘s article was titled “41 Stocks Moving In Tuesday’s Mid-Day Session” and announced on June 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: